Roivant Sciences ROIV Ratios & Valuation
| TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | TTM Q4 '24 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Free cash flow margin | -22,499.4%-6,278pp | -16,221.1%-3,206pp | -13,015%-1,750pp | -11,265.2%-1,735pp | -9,529.9%-1,367pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 123.3×-15.1× | 138.4×-7.2× | 145.6×+23.3× | 122.3×+12.6× | 109.7×+8.2× | |
| Quick ratio | 123.3×-15.1× | 138.4×-7.2× | 145.6×+23.3× | 122.3×+12.8× | 109.6×+8.4× | |
| Cash ratio | 7.2×+4.4× | 2.8×-0.1× | 2.9×+0.5× | 2.4×-25.6× | 28×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | |
| Per Share | ||||||
| Book value per share | $25.45+0.2% | $25.38-4.0% | $26.44-2.2% | $27.04-2.1% | $27.60-2.5% | |
| Valuation | ||||||
| Market capitalization | $53.09B+31.2% | $40.47B+19.1% | $33.99B+5.7% | $32.15B+0.2% | $32.08B-3.8% | |
| Enterprise value | $51.8B+27.9% | $40.49B+19.1% | $34B+5.9% | $32.09B+20.2% | $26.7B-5.6% | |
| Price / sales | 4,379.9×+2,152× | 2,227.6×+852× | 1,376×+279× | 1,097×+123× | 974.1×+78.1× | |
| Price / book | 12.1×+2.8× | 9.2×+1.9× | 7.4×+0.7× | 6.6×+0.4× | 6.3×+0.1× | |
| EV / sales | 4,222.4×+1,993× | 2,229.2×+853× | 1,376.3×+281× | 1,095.6×+270× | 825.7×+71.9× | |
| Free cash flow yield | -27.4%+7.9pp | -35.3%+4.0pp | -39.3%+1.6pp | -40.9%-1.8pp | -39.1%-2.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Roivant Sciences's ratios come from?
- Every ratio is computed from Roivant Sciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
